Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma
Endocrinology and Metabolism
;
: 202-205, 2014.
Artigo
em Inglês
| WPRIM
| ID: wpr-55017
ABSTRACT
Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of a patient who exhibited a wax and wane pattern of hypoglycemia that was attributed to sorafenib therapy. A 32-year-old woman with metastatic hemangiopericytoma visited the emergency department in a stuporous state. Nonhyperinsulinemic hypoglycemia was diagnosed, was exacerbated shortly after sorafenib therapy, and was improved by the cessation of sorafenib with additional glucocorticoid therapy. Patients with metastatic hemangiopericytoma should be carefully monitored with particular attention to hypoglycemia when sorafenib therapy is initiated.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Serviço Hospitalar de Emergência
/
Estupor
/
Hemangiopericitoma
/
Hipoglicemia
Limite:
Adulto
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Endocrinology and Metabolism
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS